medical news

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease

BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the U.S. Food and Drug Administration (FDA) recently authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer’s Disease …

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease Read More